Chronic hepatitis B and liver cancer screening: when to ask about ultrasound and AFP

Why liver cancer screening matters in chronic hepatitis B

Chronic hepatitis B increases the risk of hepatocellular carcinoma. People with cirrhosis, a family history of liver cancer, older age, long-term viral replication, or other liver risk factors should discuss screening with a clinician. The purpose is not to create fear, but to find treatable problems earlier in people at higher risk.

Screening plans are not identical for everyone with chronic hepatitis B. Clinicians usually consider age, sex, place of birth or long-term residence, family history, cirrhosis or significant fibrosis, HBV DNA, ALT, platelets, imaging, and past history.

Common screening tests

AASLD hepatocellular carcinoma guidance recommends surveillance with liver ultrasound plus AFP for eligible high-risk groups, commonly at about 6-month intervals. Hepatitis B Foundation patient resources also emphasize that AFP alone is not sensitive or specific enough to serve as the only liver cancer screening or diagnostic test.

A normal AFP does not completely rule out risk, and an elevated AFP does not automatically mean liver cancer. Ultrasound and AFP are screening tools. Abnormal findings need interpretation with further imaging, trends, and individual risk.

Why 6 months is often used

Many guidelines and patient resources use 6 months as a common surveillance interval. This timing tries to balance earlier detection with avoiding unnecessary testing. Do not skip long-term follow-up just because the last ultrasound was normal, and do not increase the frequency on your own without medical advice.

If you already have cirrhosis, prior liver cancer treatment, a small nodule on ultrasound, persistently rising AFP, or higher risk according to your clinician, your plan may be different. Follow the schedule given by the clinician responsible for your care.

How to prepare for the test

When scheduling, ask whether it is a liver ultrasound, whether AFP will be drawn at the same time, and whether fasting is needed. Bring prior ultrasound, CT/MRI, AFP, ALT/AST, platelets, HBV DNA, fibrosis assessment, and medication records. Put dates and results into one table so trends are easier to see.

If tests are done at different hospitals, save both reports and original imaging files when possible. Liver nodules, AFP values, and ultrasound visibility need comparison over time; a single phrase such as no obvious abnormality may not be enough context.

If the result is abnormal

Do not focus only on the AFP number, and do not diagnose yourself because the report mentions a nodule, lesion, or low-echo area. The next step is usually to contact the clinician promptly and ask whether short-interval follow-up, contrast CT, contrast MRI, contrast ultrasound, or referral to a liver or multidisciplinary team is needed.

Seek care quickly if the report suggests malignancy, a liver mass, portal vein abnormality, clearly or persistently elevated AFP, or if you also have new jaundice, abdominal swelling, weight loss, or right upper abdominal pain. Supplements, herbs, and detox products should not replace diagnostic evaluation.

Seven questions to ask

1. Based on my age, sex, family history, fibrosis status, and HBV DNA, am I in a group that needs liver cancer screening?
2. Should my screening be ultrasound plus AFP, or do I need another imaging method? Why?
3. How often should I be screened? If this result is normal, what is the next date?
4. If ultrasound quality is limited by obesity, fatty liver, or cirrhosis nodules, should another method be used?
5. What does normal or elevated AFP mean for me, and which changes should trigger earlier contact?
6. If a small nodule is found, should the next step be short-interval follow-up or contrast CT/MRI?
7. Do family members need screening or vaccination because of hepatitis B, family liver cancer history, or other risks?

Action checklist

Put the next liver ultrasound and AFP date on your calendar. Save every report and imaging file. Bring HBV DNA, ALT/AST, platelets, and fibrosis assessment to follow-up. Ask whether you are in a high-risk screening group. If the report is abnormal, complete recommended imaging or referral promptly instead of interpreting or delaying it on your own.